Background/Objectives: This study compared the image quality of conventional multiplexed sensitivity-encoding diffusion-weighted imaging (MUSE-DWI) and deep learning MUSE-DWI with that of vendor-specific deep learning (DL) reconstruction applied to bladder MRI. Methods: This retrospective study included 57 patients with a visible bladder mass. DWI images were reconstructed using a vendor-provided DL algorithm (AIRTM Recon DL; GE Healthcare)—a CNN-based algorithm that reduces noise and enhances image quality—applied here as a prototype for MUSE-DWI. Two radiologists independently assessed qualitative features using a 4-point scale. For the quantitative analysis, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), signal intensity ratio (SIR), and apparent diffusion coefficient (ADC) of the bladder lesions were recorded by two radiologists. The weighted kappa test and intraclass correlation were used to evaluate the interobserver agreement in the qualitative and quantitative analyses, respectively. Wilcoxon signed-rank test was used to compare the image quality of the two sequences. Results: DL MUSE-DWI demonstrated significantly improved qualitative image quality, with superior sharpness and lesion conspicuity. There were no significant differences in the distortion or artifacts. The qualitative analysis of the images by the two radiologists was in good to excellent agreement (κ ≥ 0.61). Quantitative analysis revealed higher SNR, CNR, and SIR in DL MUSE-DWI than in MUSE-DWI. The ADC values were significantly higher in DL MUSE-DWI. Interobserver agreement was poor (ICC ≤ 0.32) for SNR and CNR and excellent (ICC ≥ 0.85) for SIR and ADC values in both DL MUSE-DWI and MUSE-DWI. Conclusions: DL MUSE-DWI significantly enhanced the image quality in terms of lesion sharpness, conspicuity, SNR, CNR, and SIR, making it a promising tool for clinical imaging.
Bladder cancer is a common malignancy with high recurrence rates and significant morbidity, necessitating accurate diagnostic and prognostic tools. Although cystoscopy and transurethral resection of bladder tumor (TURBT) remain reference standards, these approaches are invasive and limited by sampling errors and understaging. Consequently, there is growing interest in non-invasive biomarkers, including urine-based assays, blood-based markers, and imaging-derived parameters. Among these biomarkers, multiparametric magnetic resonance imaging (mpMRI), particularly with the Vesical Imaging Reporting and Data System (VI-RADS), has emerged as a robust non-invasive imaging biomarker for local staging and risk stratification. Recent evidence suggests that mpMRI plays a role in predicting treatment response and recurrence, particularly in the context of neoadjuvant therapy. This review provides a comprehensive overview of current non-invasive diagnostic and prognostic biomarkers in bladder cancer, with a particular emphasis on imaging biomarkers. We discuss their clinical utility, limitations, and future integration into multimodal decision-making frameworks.